EE68 Assessment of the Cost Utility of Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Preterm Infants Born 29-35 Weeks' Gestational Age in the Philippines
Abstract
Authors
Sheryl Del Rosario-Famadico Xavier Carbonell-Estrany Bosco Paes Jean-Eric Tarride Barry Rodgers-Gray Ian Keary John Fullarton